Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.44 |
| ▸ | BMP1 | P13497 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 3/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901070 | 0.92 | PTGS1 (0.43) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL8494001 | 0.92 | GLO1 (0.49) | GLO1BMP1PTGS1GSTK1 | |
| SCHEMBL2804512 | 0.92 | GLO1 (0.49) | GLO1BMP1PTGS1GSTK1 | |
| SCHEMBL6129326 | 0.92 | PTGS1 (0.43) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL16094750 | 0.92 | PTGS1 (0.43) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL6676528 | 0.89 | PTGS1 (0.41) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL29697132 | 0.89 | PTGS1 (0.44) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL148088 | 0.89 | PTGS1 (0.44) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL5507559 | 0.88 | PTGS1 (0.40) | GLO1PTGS1GSTK1ECE1GRIA1 | |
| SCHEMBL9180258 | 0.88 | PTGS1 (0.40) | GLO1PTGS1GSTK1ECE1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11807899-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited | 2023-11-07 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220145378-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | GLO1 14/4885BMP1 1248/4885PTGS1 272/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | GLO1 14/4885BMP1 1248/4885PTGS1 272/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | GLO1 14/4885BMP1 1248/4885PTGS1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.